REGISTER RECORD · ctis
2025-523117-28-00
A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma (DREAMM-15)
AS THE REGISTER RECORDS IT
Status and dates
| Status as listed | The register records no status for this entry. |
|---|---|
| Register last updated | 2026-06-10 |
| Retrieved by this site | 2026-10-03 |
| Source | https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2025-523117-28-00 |
What this record shows
This entry describes research activity. It is not a statement about market authorisation, and it is not regulatory, legal or medical advice: a trial being listed, completed or halted says nothing about whether a substance may be sold or used anywhere. Status wording is reproduced as the register writes it and is never mapped onto a simpler vocabulary.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.